Scientific Publications

ACE publishes key technical evaluations and processes in scientific journals and often presents scientific content at regional and international symposiums and conferences.

Journal Publications

Title

Date of publication

Horizon Scanning To Nominate Subsidy Evaluation Topics For Medical Technologies: Early Experience From Singapore
January 2023 
Real-world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes November 2022 
Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore August 2022 
Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore July 2022 
Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study March 2022 
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
December 2021
Cost-effectiveness analysis of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore September 2021 
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
April 2021
A review of implementation frameworks to operationalize health technology assessment recommendations for medical technologies in the Singapore setting
April 2021
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer March 2021

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

February 2021

Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore

October 2020

Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore

October 2020

Cost-effectiveness analysis of osimertinib for first line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

September 2020

Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective

August 2020

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer

June 2020

Cost-effectiveness analysis of atezolizumab in advanced triple negative breast cancer

June 2020

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore

May 2020

Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore

May 2020

Cost effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore

August 2019

Health technology assessment and its use in drug policies: Singapore 

May 2019

Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore

March 2019

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis

October 2018

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

March 2018

Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

October 2017


Conference Posters


Title

Conference

 Date

Funding of treatments for rare diseases in Singapore 17th HTA International Annual Meeting, Beijing, China (Virtual) June 2020
Meta-Analysis of omalizumab and ciclosporin for chronic spontaneous urticaria 16th HTA International Annual Meeting in Cologne, Germany June 2019
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) in chronic obstructive pulmonary disease: A systematic review and network meta-analysis 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
Fluorodeoxyglucose positron emission tomography with computerised tomography for oncological indications: a pragmatic approach to guide subsidy decisions 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
A pilot trial of value-based pricing for medical devices 15th HTA International Annual Meeting in Vancouver, Canada June 2018
Selection of non-drug medical technologies for evaluation in Singapore 15th HTA International Annual Meeting in Vancouver, Canada June 2018
Evolution of national drug evaluation processes in Singapore 15th HTA International Annual Meeting in Vancouver, Canada June 2018